Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Nutrien Ltd — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Nutrien Ltd trades at $68.67 (market cap $32.62B). The key difference: Nutrien Ltd is far larger — about 4.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Nutrien Ltd pays a 3.21% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | NTR | |
|---|---|---|
Market Cap | $8.04B | $32.62B |
Sector | Health | Basic Materials |
52-Week High | $339.75 | $83.94 |
52-Week Low | $241.71 | $53.64 |
Enterprise Value | $7.85B | $45.79B |
Dividend Yield | — | 3.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Nutrien (NTR) trades at $67.60, up 3.32% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 13.77 and net income margin of 8.58%. Recent earnings beat expectations in Q1 2026, and analyst consensus is strongly positive with a $79.50 price target. The company maintains solid cash flow from operations at $4.01 billion despite recent net cash outflows.
NTR presents a compelling value opportunity with reasonable valuation metrics and strong analyst support. Key risks include volatile fertilizer prices and global agricultural demand fluctuations. The upcoming Q2 2026 earnings report with expected EPS of $2.89 represents a significant near-term catalyst for price movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
